WJMSC
Phase 1Biologic
WJMSC is one of 46 biologic programs targeting Autism. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
109 competitors in Autism
#DrugCompanyPhaseTrials
1Pitocin
RRetrophin
Phase 3
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Bumex
VValidus Pharmaceuticals
Phase 3
Luvox
SSolvay Pharmaceuticals
Phase 3
Reminyl
WWim Janssens
Phase 3
Zoloft
VViatris Specialty LLC
Phase 3
Latuda
SSunovion Respiratory Development Inc.
Phase 3
Paliperidone ER
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Folinic Acid
RochePhase 3
Kuvan
BioMarin PharmaceuticalPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for WJMSC. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- UUniversity of Jordan